|
1
|
Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
|
Int J Pharm
|
2011
|
1.38
|
|
2
|
Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors.
|
Br J Pharmacol
|
2005
|
1.15
|
|
3
|
Quantitative analysis of binding parameters of [3H]N-methylscopolamine in central nervous system of muscarinic acetylcholine receptor knockout mice.
|
Brain Res Mol Brain Res
|
2005
|
1.02
|
|
4
|
Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability.
|
J Pharm Sci
|
2010
|
0.94
|
|
5
|
Cordycepin (3'-deoxyadenosine) inhibits the growth of B16-BL6 mouse melanoma cells through the stimulation of adenosine A3 receptor followed by glycogen synthase kinase-3beta activation and cyclin D1 suppression.
|
Naunyn Schmiedebergs Arch Pharmacol
|
2007
|
0.93
|
|
6
|
Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder.
|
J Urol
|
2006
|
0.92
|
|
7
|
A possible mechanism for decrease in serum thyroxine level by polychlorinated biphenyls in Wistar and Gunn rats.
|
Toxicol Sci
|
2004
|
0.90
|
|
8
|
Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers.
|
J Clin Pharmacol
|
2006
|
0.89
|
|
9
|
Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice.
|
Br J Pharmacol
|
2005
|
0.89
|
|
10
|
Activation of muscarinic M-1 cholinoceptors by curcumin to increase contractility in urinary bladder isolated from Wistar rats.
|
Neurosci Lett
|
2010
|
0.88
|
|
11
|
Mouse strain differences in immobility and sensitivity to fluvoxamine and desipramine in the forced swimming test: analysis of serotonin and noradrenaline transporter binding.
|
Eur J Pharmacol
|
2008
|
0.88
|
|
12
|
Functional analysis of muscarinic acetylcholine receptors using knockout mice.
|
Life Sci
|
2004
|
0.88
|
|
13
|
Internalization of basic fibroblast growth factor at the mouse blood-brain barrier involves perlecan, a heparan sulfate proteoglycan.
|
J Neurochem
|
2002
|
0.88
|
|
14
|
VAT-1 is a novel pathogenic factor of progressive benign prostatic hyperplasia.
|
Prostate
|
2011
|
0.88
|
|
15
|
Effects of green tea catechins on cytochrome P450 2B6, 2C8, 2C19, 2D6 and 3A activities in human liver and intestinal microsomes.
|
Drug Metab Pharmacokinet
|
2012
|
0.87
|
|
16
|
Hepatic UDP-glucuronosyltransferases responsible for glucuronidation of thyroxine in humans.
|
Drug Metab Dispos
|
2007
|
0.87
|
|
17
|
Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion.
|
J Pharmacol Exp Ther
|
2005
|
0.87
|
|
18
|
Antinociceptive effects of St. John's wort, Harpagophytum procumbens extract and Grape seed proanthocyanidins extract in mice.
|
Biol Pharm Bull
|
2008
|
0.87
|
|
19
|
Involvement of dopamine receptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test.
|
Eur J Pharmacol
|
2004
|
0.86
|
|
20
|
Structure-activity relationships of receptor binding of 1,4-dihydropyridine derivatives.
|
Biol Pharm Bull
|
2008
|
0.86
|
|
21
|
Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
|
Eur J Pharmacol
|
2005
|
0.86
|
|
22
|
Coleus forskohlii extract induces hepatic cytochrome P450 enzymes in mice.
|
Food Chem Toxicol
|
2011
|
0.85
|
|
23
|
Selective protection of curcumin against carbon tetrachloride-induced inactivation of hepatic cytochrome P450 isozymes in rats.
|
Life Sci
|
2005
|
0.85
|
|
24
|
Effects of continuous administration of paroxetine on ligand binding site and expression of serotonin transporter protein in mouse brain.
|
Brain Res
|
2005
|
0.85
|
|
25
|
Isolation and pharmacological characterization of fatty acids from saw palmetto extract.
|
Anal Sci
|
2009
|
0.85
|
|
26
|
In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy.
|
J Control Release
|
2009
|
0.85
|
|
27
|
Hepatic cytochrome P450 mediates interaction between warfarin and Coleus forskohlii extract in vivo and in vitro.
|
J Pharm Pharmacol
|
2012
|
0.84
|
|
28
|
Blood-brain permeability of [3H]-(3-methyl-His2)thyrotropin-releasing hormone (MeTRH) in mice: effects of TRH and its analogues.
|
Drug Metab Pharmacokinet
|
2003
|
0.84
|
|
29
|
Pharmacological effects of Hachi-mi-jio-gan extract (Harncare) on the contractile response and on pharmacologically relevant receptors in the rat bladder.
|
Yakugaku Zasshi
|
2009
|
0.84
|
|
30
|
Ginkgo biloba extract attenuates warfarin-mediated anticoagulation through induction of hepatic cytochrome P450 enzymes by bilobalide in mice.
|
Phytomedicine
|
2011
|
0.84
|
|
31
|
Liposomal formulations of glucagon-like peptide-1: improved bioavailability and anti-diabetic effect.
|
Int J Pharm
|
2009
|
0.84
|
|
32
|
Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography.
|
Life Sci
|
2010
|
0.84
|
|
33
|
Effects of dietary ingredients on function and expression of P-glycoprotein in human intestinal epithelial cells.
|
Biol Pharm Bull
|
2010
|
0.83
|
|
34
|
Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD.
|
Peptides
|
2007
|
0.83
|
|
35
|
Quantitative analysis of the loss of muscarinic receptors in various peripheral tissues in M1-M5 receptor single knockout mice.
|
Br J Pharmacol
|
2009
|
0.83
|
|
36
|
Natural vanadium-containing Mt. Fuji ground water improves hypo-activity of liver insulin receptor in Goto-Kakisaki rats.
|
Mol Cell Biochem
|
2004
|
0.83
|
|
37
|
Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach.
|
Int J Pharm
|
2010
|
0.83
|
|
38
|
Binding activities by propiverine and its N-oxide metabolites of L-type calcium channel antagonist receptors in the rat bladder and brain.
|
Life Sci
|
2007
|
0.82
|
|
39
|
Physicochemical and pharmacokinetic characterization of water-soluble Coenzyme Q(10) formulations.
|
Int J Pharm
|
2008
|
0.82
|
|
40
|
Development of rapid and simultaneous quantitative method for green tea catechins on the bioanalytical study using UPLC/ESI-MS.
|
Biomed Chromatogr
|
2012
|
0.82
|
|
41
|
Induction and recovery of hepatic drug metabolizing enzymes in rats treated with Ginkgo biloba extract.
|
Food Chem Toxicol
|
2004
|
0.82
|
|
42
|
Establishment and intra-/inter-laboratory validation of a standard protocol of reactive oxygen species assay for chemical photosafety evaluation.
|
J Appl Toxicol
|
2012
|
0.82
|
|
43
|
Relationship between development of nephrotoxicity and blood concentration of cyclosporine A in bone-marrow transplanted recipients who received the continuous intravenous infusion.
|
Biol Pharm Bull
|
2003
|
0.82
|
|
44
|
In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment.
|
J Pharmacol Exp Ther
|
2008
|
0.82
|
|
45
|
Reactive oxygen species assay-based risk assessment of drug-induced phototoxicity: classification criteria and application to drug candidates.
|
J Pharm Biomed Anal
|
2008
|
0.82
|
|
46
|
Effect of oxybutynin and imidafenacin on central muscarinic receptor occupancy and cognitive function: a monkey PET study with [(11)C](+)3-MPB.
|
Neuroimage
|
2011
|
0.81
|
|
47
|
Novel crystalline solid dispersion of tranilast with high photostability and improved oral bioavailability.
|
Eur J Pharm Sci
|
2009
|
0.81
|
|
48
|
High-throughput reactive oxygen species (ROS) assay: an enabling technology for screening the phototoxic potential of pharmaceutical substances.
|
J Pharm Biomed Anal
|
2007
|
0.81
|
|
49
|
In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder.
|
Naunyn Schmiedebergs Arch Pharmacol
|
2007
|
0.81
|
|
50
|
Inhalable dry-emulsion formulation of cyclosporine A with improved anti-inflammatory effects in experimental asthma/COPD-model rats.
|
Eur J Pharm Biopharm
|
2011
|
0.81
|
|
51
|
Pharmacologically relevant receptor binding characteristics and 5alpha-reductase inhibitory activity of free Fatty acids contained in saw palmetto extract.
|
Biol Pharm Bull
|
2009
|
0.81
|
|
52
|
Investigation of the bioactive conformation of histamine H3 receptor antagonists by the cyclopropylic strain-based conformational restriction strategy.
|
J Med Chem
|
2010
|
0.81
|
|
53
|
In vitro and in vivo characterization of new formulations of St. John's Wort extract with improved pharmacokinetics and anti-nociceptive effect.
|
Drug Metab Pharmacokinet
|
2011
|
0.81
|
|
54
|
Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications.
|
Naunyn Schmiedebergs Arch Pharmacol
|
2008
|
0.80
|
|
55
|
Effects of oral administration of extracts of Hypericum perforatum (St John's wort) on brain serotonin transporter, serotonin uptake and behaviour in mice.
|
J Pharm Pharmacol
|
2004
|
0.80
|
|
56
|
A novel mechanism for polychlorinated biphenyl-induced decrease in serum thyroxine level in rats.
|
Drug Metab Dispos
|
2007
|
0.80
|
|
57
|
In vivo measurement of 1,4-dihydropyridine receptors in mesenteric arteries of spontaneously hypertensive rats and effect of nifedipine and cilnidipine.
|
Biol Pharm Bull
|
2002
|
0.80
|
|
58
|
Physicochemical and pharmacological characterization of novel vasoactive intestinal peptide derivatives with improved stability.
|
Eur J Pharm Biopharm
|
2009
|
0.80
|
|
59
|
Onset of clinical effects and plasma concentration of fluvoxamine in Japanese patients.
|
Biol Pharm Bull
|
2010
|
0.80
|
|
60
|
Anti-androgenic effects of S-40542, a novel non-steroidal selective androgen receptor modulator (SARM) for the treatment of benign prostatic hyperplasia.
|
Prostate
|
2012
|
0.80
|
|
61
|
Ginkgo biloba extract modifies hypoglycemic action of tolbutamide via hepatic cytochrome P450 mediated mechanism in aged rats.
|
Life Sci
|
2004
|
0.80
|
|
62
|
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide attenuate the cigarette smoke extract-induced apoptotic death of rat alveolar L2 cells.
|
Eur J Biochem
|
2004
|
0.80
|
|
63
|
In vitro photochemical and phototoxicological characterization of major constituents in St. John's Wort (Hypericum perforatum) extracts.
|
Phytochemistry
|
2011
|
0.79
|
|
64
|
Alteration of muscarinic and purinergic receptors in urinary bladder of rats with cyclophosphamide-induced interstitial cystitis.
|
Neurosci Lett
|
2008
|
0.79
|
|
65
|
Development of micellar reactive oxygen species assay for photosafety evaluation of poorly water-soluble chemicals.
|
Toxicol In Vitro
|
2013
|
0.79
|
|
66
|
Neuroprotective effect and brain receptor binding of taltirelin, a novel thyrotropin-releasing hormone (TRH) analogue, in transient forebrain ischemia of C57BL/6J mice.
|
Life Sci
|
2002
|
0.79
|
|
67
|
Photosafety assessments on pirfenidone: photochemical, photobiological, and pharmacokinetic characterization.
|
J Photochem Photobiol B
|
2013
|
0.79
|
|
68
|
Long-acting analogue of vasoactive intestinal peptide, [R15, 20, 21, L17]-VIP-GRR (IK312532), protects rat alveolar L2 cells from the cytotoxicity of cigarette smoke.
|
Regul Pept
|
2004
|
0.79
|
|
69
|
Physicochemical and pharmacological characterization of alpha-tocopherol-loaded nano-emulsion system.
|
Int J Pharm
|
2010
|
0.79
|
|
70
|
Improvement by phytotherapeutic agent of detrusor overactivity, down-regulation of pharmacological receptors and urinary cytokines in rats with cyclophosphamide induced cystitis.
|
J Urol
|
2012
|
0.79
|
|
71
|
Novel dry powder formulation of ovalbumin for development of COPD-like animal model: Physicochemical characterization and biomarker profiling in rats.
|
Eur J Pharm Sci
|
2009
|
0.79
|
|
72
|
In vivo demonstration of muscarinic receptor binding activity of N-desethyl-oxybutynin, active metabolite of oxybutynin.
|
Life Sci
|
2005
|
0.79
|
|
73
|
Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects.
|
Eur J Clin Pharmacol
|
2009
|
0.78
|
|
74
|
Dietary Coleus forskohlii extract generates dose-related hepatotoxicity in mice.
|
J Appl Toxicol
|
2012
|
0.78
|
|
75
|
Comparative assessment of empirical and physiological approaches on predicting human clearances.
|
J Pharm Sci
|
2010
|
0.78
|
|
76
|
Different distribution of morphine and morphine-6 beta-glucuronide after intracerebroventricular injection in rats.
|
Br J Pharmacol
|
2003
|
0.78
|
|
77
|
Comparative evaluation of exocrine muscarinic receptor binding characteristics and inhibition of salivation of solifenacin in mice.
|
Biol Pharm Bull
|
2006
|
0.78
|
|
78
|
Modulation of phenotype of human prostatic stromal cells by transforming growth factor-betas.
|
Prostate
|
2004
|
0.78
|
|
79
|
Formulation design and in vivo evaluation of dry powder inhalation system of new vasoactive intestinal peptide derivative ([R(15, 20, 21), L(17), A(24,25), des-N(28)]-VIP-GRR) in experimental asthma/COPD model rats.
|
Int J Pharm
|
2011
|
0.78
|
|
80
|
Alpha-helical structure in the C-terminus of vasoactive intestinal peptide: functional and structural consequences.
|
Eur J Pharmacol
|
2004
|
0.78
|
|
81
|
Cyclopropane-based conformational restriction of GABA by a stereochemical diversity-oriented strategy: identification of an efficient lead for potent inhibitors of GABA transports.
|
Bioorg Med Chem
|
2013
|
0.78
|
|
82
|
The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: bladder selectivity based on in vivo drug-receptor binding characteristics of antimuscarinic agents for treatment of overactive bladder.
|
J Pharmacol Sci
|
2010
|
0.78
|
|
83
|
Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder.
|
J Urol
|
2004
|
0.78
|
|
84
|
Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes.
|
Drug Metab Pharmacokinet
|
2010
|
0.78
|
|
85
|
Inhalable powder formulation of pirfenidone with reduced phototoxic risk for treatment of pulmonary fibrosis.
|
Pharm Res
|
2013
|
0.78
|
|
86
|
Inhalable sustained-release formulation of long-acting vasoactive intestinal peptide derivative alleviates acute airway inflammation.
|
Peptides
|
2012
|
0.78
|
|
87
|
Relationship between prostatic alpha(1)-adrenoceptor binding and reduction in intraurethral pressure following continuous infusion of KMD-3213 in rats.
|
Pharmacology
|
2002
|
0.78
|
|
88
|
Assay of catechol-O-methyltransferase activity in human erythrocytes using norepinephrine as a natural substrate.
|
Ann Clin Biochem
|
2002
|
0.78
|
|
89
|
Combined use of in vitro phototoxic assessments and cassette dosing pharmacokinetic study for phototoxicity characterization of fluoroquinolones.
|
AAPS J
|
2011
|
0.78
|
|
90
|
Green tea extract affects the cytochrome P450 3A activity and pharmacokinetics of simvastatin in rats.
|
Drug Metab Pharmacokinet
|
2013
|
0.78
|
|
91
|
Pharmacokinetic study of nicotine and its metabolite cotinine to clarify possible association between smoking and voiding dysfunction in rats using UPLC/ESI-MS.
|
Drug Metab Pharmacokinet
|
2011
|
0.78
|
|
92
|
Inhalable powder formulation of vasoactive intestinal peptide derivative, [R15,20,21, L17]-VIP-GRR, attenuated neutrophilic airway inflammation in cigarette smoke-exposed rats.
|
Eur J Pharm Sci
|
2010
|
0.78
|
|
93
|
High-throughput screening strategy for photogenotoxic potential of pharmaceutical substances using fluorescent intercalating dye.
|
J Pharm Biomed Anal
|
2010
|
0.78
|
|
94
|
Pharmacokinetic and pharmacodynamic analysis of acetylcholinesterase inhibition by distigmine bromide in rats.
|
Drug Metab Pharmacokinet
|
2010
|
0.78
|
|
95
|
Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: anti-inflammatory effect in experimental asthmatic rats.
|
Peptides
|
2009
|
0.78
|
|
96
|
Polychlorinated biphenyl-mediated decrease in serum thyroxine level in rodents.
|
Drug Metab Dispos
|
2009
|
0.78
|
|
97
|
Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine.
|
Life Sci
|
2007
|
0.78
|
|
98
|
Loss of muscarinic and purinergic receptors in urinary bladder of rats with hydrochloric acid-induced cystitis.
|
Urology
|
2010
|
0.78
|
|
99
|
Drug-induced phototoxicity; an early in vitro identification of phototoxic potential of new drug entities in drug discovery and development.
|
Curr Drug Saf
|
2009
|
0.78
|
|
100
|
Time-dependent induction of hepatic cytochrome P450 enzyme activity and mRNA expression by bilobalide in rats.
|
J Pharmacol Sci
|
2009
|
0.78
|
|
101
|
Novel dry powder inhaler formulation of glucagon with addition of citric acid for enhanced pulmonary delivery.
|
Int J Pharm
|
2009
|
0.77
|
|
102
|
Novel vasoactive intestinal peptide derivatives with improved stability protect rat alveolar L2 cells from cigarette smoke-induced cytotoxicity and apoptosis.
|
Peptides
|
2010
|
0.77
|
|
103
|
Decrease in serum thyroxine level by phenobarbital in rats is not necessarily dependent on increase in hepatic UDP-glucuronosyltransferase.
|
Drug Metab Dispos
|
2005
|
0.77
|
|
104
|
Improved dissolution and pharmacokinetic behavior of dipyridamole formulation with microenvironmental pH-modifier under hypochlorhydria.
|
Int J Pharm
|
2012
|
0.77
|
|
105
|
Misinterpretation of the effect of amlodipine on cytosolic calcium concentration with fura-2 fluorospectrometry.
|
Naunyn Schmiedebergs Arch Pharmacol
|
2008
|
0.77
|
|
106
|
Overview of green tea interaction with cardiovascular drugs.
|
Curr Pharm Des
|
2015
|
0.77
|
|
107
|
Inhalable sustained-release formulation of glucagon: in vitro amyloidogenic and inhalation properties, and in vivo absorption and bioactivity.
|
Pharm Res
|
2011
|
0.77
|
|
108
|
In vitro/in vivo phototoxic risk assessments of griseofulvin based on photobiochemical and pharmacokinetic behaviors.
|
Eur J Pharm Sci
|
2009
|
0.77
|
|
109
|
Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
|
J Urol
|
2007
|
0.77
|
|
110
|
[Effects of various ginkgo biloba extracts and proanthocyanidin on hepatic cytochrome P450 activity in rats].
|
Shokuhin Eiseigaku Zasshi
|
2004
|
0.77
|
|
111
|
Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice.
|
Eur J Pharmacol
|
2009
|
0.77
|
|
112
|
Physicochemical and biopharmaceutical characterization of amorphous solid dispersion of nobiletin, a citrus polymethoxylated flavone, with improved hepatoprotective effects.
|
Eur J Pharm Sci
|
2013
|
0.77
|
|
113
|
Effects of saw palmetto extract on micturition reflex of rats and its autonomic receptor binding activity.
|
J Urol
|
2005
|
0.77
|
|
114
|
A possible mechanism for 2,2',4,4',5,5'-hexachlorobiphenyl-mediated decrease in serum thyroxine level in mice.
|
Toxicol Appl Pharmacol
|
2011
|
0.77
|
|
115
|
New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy.
|
Expert Opin Drug Deliv
|
2009
|
0.77
|
|
116
|
A novel method using confocal laser scanning microscopy for sensitive measurement of P-glycoprotein-mediated transport activity in Caco-2 cells.
|
J Pharm Pharmacol
|
2011
|
0.77
|
|
117
|
Contribution of cytochrome P450 and UDT-glucuronosyltransferase to the metabolism of drugs containing carboxylic acid groups: risk assessment of acylglucuronides using human hepatocytes.
|
Xenobiotica
|
2014
|
0.77
|
|
118
|
Comparative measurement of spinal CSF microdialysate concentrations and concomitant antinociception of morphine and morphine-6beta-glucuronide in rats.
|
Life Sci
|
2007
|
0.77
|
|
119
|
Comparative studies on physicochemical stability of cyclosporine A-loaded amorphous solid dispersions.
|
Int J Pharm
|
2012
|
0.77
|
|
120
|
Self-assembled micellar formulation of chafuroside A with improved anti-inflammatory effects in experimental asthma/COPD-model rats.
|
Eur J Pharm Sci
|
2011
|
0.77
|
|
121
|
High-throughput screening system for identifying phototoxic potential of drug candidates based on derivatives of reactive oxygen metabolites.
|
Pharm Res
|
2010
|
0.77
|
|
122
|
Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients.
|
Biol Pharm Bull
|
2010
|
0.77
|
|
123
|
Development of PACAP38 analogue with improved stability: physicochemical and in vitro/in vivo pharmacological characterization.
|
J Mol Neurosci
|
2010
|
0.77
|
|
124
|
Muscarinic Receptor Binding in Rat Bladder Urothelium and Detrusor Muscle by Intravesical Solifenacin.
|
Biol Pharm Bull
|
2016
|
0.77
|
|
125
|
St. John's wort promotes adipocyte differentiation and modulates NF-κB activation in 3T3-L1 cells.
|
Biol Pharm Bull
|
2014
|
0.76
|
|
126
|
Development of meloxicam salts with improved dissolution and pharmacokinetic behaviors in rats with impaired gastric motility.
|
Pharm Res
|
2012
|
0.76
|
|
127
|
In vivo identification and characterization of binding sites for selective serotonin reuptake inhibitors in mouse brain.
|
Life Sci
|
2004
|
0.76
|
|
128
|
Novel methodology for predicting photogenotoxic risk of pharmaceutical substances based on reactive oxygen species (ROS) and DNA-binding assay.
|
J Pharm Sci
|
2009
|
0.76
|
|
129
|
4-Hydroxy-2,2',3,4',5,5',6-heptachlorobiphenyl-mediated decrease in serum thyroxine level in mice occurs through increase in accumulation of thyroxine in the liver.
|
Drug Metab Dispos
|
2009
|
0.76
|
|
130
|
Novel solid self-emulsifying drug delivery system of coenzyme Q₁₀ with improved photochemical and pharmacokinetic behaviors.
|
Eur J Pharm Sci
|
2012
|
0.76
|
|
131
|
In vitro/in vivo characterization of nanocrystalline formulation of tranilast with improved dissolution and hepatoprotective properties.
|
Eur J Pharm Biopharm
|
2013
|
0.76
|
|
132
|
Development of dry powder inhalation system of novel vasoactive intestinal peptide (VIP) analogue for pulmonary administration.
|
Life Sci
|
2006
|
0.76
|
|
133
|
Muscarinic and alpha 1-adrenergic receptor binding characteristics of saw palmetto extract in rat lower urinary tract.
|
Urology
|
2007
|
0.76
|
|
134
|
Development of inhalable nanocrystalline solid dispersion of tranilast for airway inflammatory diseases.
|
J Pharm Sci
|
2011
|
0.76
|
|
135
|
Pharmacokinetics and pharmacodynamics of low doses of midazolam administered intravenously and orally to healthy volunteers.
|
Clin Exp Pharmacol Physiol
|
2009
|
0.76
|
|
136
|
Chemical synthesis and formulation design of a PEGylated vasoactive intestinal peptide derivative with improved metabolic stability.
|
Eur J Pharm Sci
|
2013
|
0.76
|
|
137
|
Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
|
J Med Chem
|
2006
|
0.76
|
|
138
|
Demonstration of muscarinic and nicotinic receptor binding activities of distigmine to treat detrusor underactivity.
|
Biol Pharm Bull
|
2010
|
0.76
|
|
139
|
Development of novel solid dispersion of tranilast using amphiphilic block copolymer for improved oral bioavailability.
|
Int J Pharm
|
2013
|
0.76
|
|
140
|
Monospecific antipeptide antibodies against human hepatic UDP-glucuronosyltransferase 1A subfamily (UGT1A) isoforms.
|
Drug Metab Pharmacokinet
|
2006
|
0.76
|
|
141
|
Effect of 2 weeks' consumption of pomegranate juice on the pharmacokinetics of a single dose of midazolam: an open-label, randomized, single-center, 2-period crossover study in healthy Japanese volunteers.
|
Clin Ther
|
2011
|
0.76
|
|
142
|
Respirable dry powder formulation of bleomycin for developing a pulmonary fibrosis animal model.
|
J Pharm Sci
|
2012
|
0.76
|
|
143
|
Pharmacological effects and lung-binding characteristics of a novel VIP analogue, [R15, 20, 21, L17]-VIP-GRR (IK312532).
|
Regul Pept
|
2004
|
0.76
|
|
144
|
Muscarinic receptors and their mRNAs in type 2 Goto-Kakizaki diabetic rat prostate.
|
Prostate
|
2010
|
0.76
|
|
145
|
Physicochemical and pharmacokinetic characterization of amorphous solid dispersion of tranilast with enhanced solubility in gastric fluid and improved oral bioavailability.
|
Drug Metab Pharmacokinet
|
2012
|
0.76
|
|
146
|
Development of high-energy amorphous solid dispersion of nanosized nobiletin, a citrus polymethoxylated flavone, with improved oral bioavailability.
|
J Pharm Sci
|
2011
|
0.75
|
|
147
|
Novel homodimer model of the β-adrenergic receptor in complex with free fatty acids and cholesterol: first-principles calculation studies.
|
Bioinformation
|
2012
|
0.75
|
|
148
|
Beneficial effects of Gosha-jinki-gan and green tea extract in rats with chemical cystitis.
|
J Pharmacol Sci
|
2013
|
0.75
|
|
149
|
Urodynamics and bladder muscarinic receptors in rats with cerebral infarction and bladder outlet obstruction.
|
Neurosci Lett
|
2007
|
0.75
|
|
150
|
Pharmacological effects of saw palmetto extract in the lower urinary tract.
|
Acta Pharmacol Sin
|
2009
|
0.75
|
|
151
|
Editorial comment to suppression of bladder overactivity and oxidative stress by the phytotherapeutic agent, Eviprostat, in a rat model of atherosclerosis-induced chronic bladder ischemia.
|
Int J Urol
|
2012
|
0.75
|
|
152
|
Pituitary adenylate cyclase-activating polypeptide attenuates streptozotocin-induced apoptotic death of RIN-m5F cells through regulation of Bcl-2 family protein mRNA expression.
|
FEBS J
|
2008
|
0.75
|
|
153
|
A possible mechanism for the decrease in serum thyroxine level by a 2,3,7,8-tetrachlorodibenzo-p-dioxin-like polychlorinated biphenyl congener, 3,3',4,4',5-pentachlorobiphenyl in mice.
|
Drug Metab Dispos
|
2010
|
0.75
|
|
154
|
Characterization of muscarinic receptors in the human bladder mucosa: direct quantification of subtypes using 4-DAMP mustard.
|
Urology
|
2011
|
0.75
|
|
155
|
Novel formulations of dipyridamole with microenvironmental pH-modifiers for improved dissolution and bioavailability under hypochlorhydria.
|
Int J Pharm
|
2012
|
0.75
|
|
156
|
Stable dry powder inhaler formulation of tranilast attenuated antigen-evoked airway inflammation in rats.
|
Eur J Pharm Biopharm
|
2010
|
0.75
|
|
157
|
In vitro phototoxicity of dihydropyridine derivatives: a photochemical and photobiological study.
|
Eur J Pharm Sci
|
2007
|
0.75
|
|
158
|
A possible mechanism for 2,3',4,4',5'-pentachlorobiphenyl-mediated decrease in serum thyroxine level in mice.
|
Biol Pharm Bull
|
2013
|
0.75
|
|
159
|
Involvement of the 5-HT(1A) receptor in the anti-immobility effects of fluvoxamine in the forced swimming test and mouse strain differences in 5-HT(1A) receptor binding.
|
Eur J Pharmacol
|
2009
|
0.75
|
|
160
|
Is hyperuricemia a risk factor for arteriosclerosis? Uric acid and arteriosclerosis in apolipoprotein e-deficient mice.
|
Biol Pharm Bull
|
2014
|
0.75
|
|
161
|
Bladder endothelin-1 receptor binding of bosentan and ambrisentan.
|
J Pharmacol Sci
|
2013
|
0.75
|
|
162
|
[In vivo analysis of drug-receptor binding characteristics].
|
Nihon Yakurigaku Zasshi
|
2009
|
0.75
|
|
163
|
Synthesis of 1-arylpiperazyl-2-phenylcyclopropanes designed as antidopaminergic agents: cyclopropane-based conformationally restricted analogs of haloperidol.
|
Bioorg Med Chem
|
2008
|
0.75
|
|
164
|
Development of (-)-epigallocatechin-3-gallate (EGCG)-loaded enteric microparticles with intestinal mucoadhesive property.
|
Int J Pharm
|
2011
|
0.75
|
|
165
|
A possible mechanism for the decrease in serum thyroxine level by phenobarbital in rodents.
|
Toxicol Appl Pharmacol
|
2010
|
0.75
|
|
166
|
Up-regulation of nicotinic and muscarinic receptor mRNA in rat bladder by repeated administration of nicotine in relation to the pharmacokinetics.
|
Life Sci
|
2011
|
0.75
|
|
167
|
Effects of Ginkgo biloba extract on the pharmacokinetics and pharmacodynamics of tolbutamide in protein-restricted rats.
|
J Pharm Pharmacol
|
2011
|
0.75
|
|
168
|
Cyclopropane-based stereochemical diversity-oriented conformational restriction strategy: histamine H3 and/or H4 receptor ligands with the 2,3-methanobutane backbone.
|
Org Biomol Chem
|
2011
|
0.75
|
|
169
|
Studies on the transport of thyrotropin-releasing hormone (TRH) analogues in Caco-2 cell monolayers.
|
J Pharm Pharmacol
|
2003
|
0.75
|
|
170
|
5th International Symposium on receptor mechanisms, signal transduction and drug effects.
|
Naunyn Schmiedebergs Arch Pharmacol
|
2008
|
0.75
|
|
171
|
Different effects of morphine and morphine-6beta-glucuronide on formalin-evoked spinal glutamate release in conscious and freely moving rats.
|
Neurosci Lett
|
2007
|
0.75
|
|
172
|
Muscarinic receptor binding of the novel radioligand, [3h]imidafenacin in the human bladder and parotid gland.
|
J Pharmacol Sci
|
2013
|
0.75
|
|
173
|
Three-dimensional structural diversity-oriented peptidomimetics based on the cyclopropylic strain.
|
Org Lett
|
2013
|
0.75
|
|
174
|
Effects of quinidine on antinociception and pharmacokinetics of morphine in rats.
|
J Pharm Pharmacol
|
2009
|
0.75
|
|
175
|
A simple method to evaluate reactivity of acylglucuronides optimized for early stage drug discovery.
|
Biol Pharm Bull
|
2013
|
0.75
|
|
176
|
Photosafety screening of phenothiazine derivatives with combined use of photochemical and cassette-dosing pharmacokinetic data.
|
Toxicol Sci
|
2013
|
0.75
|
|
177
|
Non-animal photosafety assessment approaches for cosmetics based on the photochemical and photobiochemical properties.
|
Toxicol In Vitro
|
2013
|
0.75
|
|
178
|
Effects of repeated morphine treatment on the antinociceptive effects, intestinal absorption, and efflux from intestinal epithelial cells of morphine.
|
Biol Pharm Bull
|
2009
|
0.75
|
|
179
|
Comparative study on 2,2',4,5,5'-pentachlorobiphenyl-mediated decrease in serum thyroxine level between C57BL/6 and its transthyretin-deficient mice.
|
Toxicol Appl Pharmacol
|
2012
|
0.75
|
|
180
|
Highly sensitive measurement of P-glycoprotein-mediated transport activity in Caco-2 cells.
|
Biol Pharm Bull
|
2010
|
0.75
|
|
181
|
The 5-HT2 receptor antagonist reduces immobility of mice treated with the atypical antidepressant mianserin in the forced swimming test.
|
Biol Pharm Bull
|
2002
|
0.75
|
|
182
|
Endothelin-1 receptors in rat tissues: characterization by bosentan, ambrisentan and CI-1020.
|
Biol Pharm Bull
|
2014
|
0.75
|
|
183
|
Development of an albuminous reactive oxygen species assay for photosafety evaluation under experimental biomimetic conditions.
|
J Appl Toxicol
|
2013
|
0.75
|
|
184
|
In vitro phototoxic potential and photochemical properties of imidazopyridine derivative: a novel 5-HT4 partial agonist.
|
J Pharm Sci
|
2008
|
0.75
|
|
185
|
Enhancement by grapefruit juice of morphine antinociception.
|
Biol Pharm Bull
|
2008
|
0.75
|
|
186
|
Synthesis and structural and pharmacological properties of cyclopropane-based conformationally restricted analogs of 4-methylhistamine as histamine H3/H4 receptor ligands.
|
Bioorg Med Chem
|
2009
|
0.75
|
|
187
|
Evaluation of the pharmacokinetic interaction of midazolam with ursodeoxycholic acid, ketoconazole and dexamethasone by brain benzodiazepine receptor occupancy.
|
J Pharm Pharmacol
|
2010
|
0.75
|
|
188
|
Effects of ursodeoxycholic acid on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam in healthy volunteers.
|
Naunyn Schmiedebergs Arch Pharmacol
|
2007
|
0.75
|
|
189
|
Microenvironmental pH-modification to improve dissolution behavior and oral absorption for drugs with pH-dependent solubility.
|
Expert Opin Drug Deliv
|
2014
|
0.75
|
|
190
|
The decrease in level of serum thyroxine by 2,2',4,5,5'-pentachlorobiphenyl in rats and mice: no correlation with formation of methylsulfonyl metabolites.
|
Drug Metab Dispos
|
2005
|
0.75
|
|
191
|
Comparative characterization of lung muscarinic receptor binding after intratracheal administration of tiotropium, ipratropium, and glycopyrrolate.
|
J Pharmacol Sci
|
2011
|
0.75
|
|
192
|
Fesoterodine, its active metabolite, and tolterodine bind selectively to muscarinic receptors in human bladder mucosa and detrusor muscle.
|
Urology
|
2013
|
0.75
|
|
193
|
Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.
|
J Med Chem
|
2003
|
0.75
|
|
194
|
New dipyridamole salt with improved dissolution and oral bioavailability under hypochlorhydric conditions.
|
Drug Metab Pharmacokinet
|
2013
|
0.75
|
|
195
|
Development of cyclosporine A-loaded dry-emulsion formulation using highly purified glycerol monooleate for safe inhalation therapy.
|
Int J Pharm
|
2013
|
0.75
|
|
196
|
Exploratory and regulatory assessments on photosafety of new drug entities.
|
Curr Drug Saf
|
2012
|
0.75
|
|
197
|
Structure-activity relationship of synthetic truncated analogues of vasoactive intestinal peptide (VIP): an enhancement in the activity by a substitution with arginine.
|
Life Sci
|
2004
|
0.75
|
|
198
|
3,3',4,4'-Tetrachlorobiphenyl-mediated decrease of serum thyroxine level in C57BL/6 and DBA/2 mice occurs mainly through enhanced accumulation of thyroxine in the liver.
|
Biol Pharm Bull
|
2013
|
0.75
|
|
199
|
Characterization of the carrier-mediated transport of ketoprofen, a nonsteroidal anti-inflammatory drug, in rabbit corneal epithelium cells.
|
J Pharm Pharmacol
|
2012
|
0.75
|
|
200
|
In vitro photobiochemical characterization of sulfobutylether-β-cyclodextrin formulation of bufexamac.
|
J Pharm Biomed Anal
|
2011
|
0.75
|